154 related articles for article (PubMed ID: 26853910)
1. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis.
Takahashi F; Tominaga K; Kanamori A; Takenaka K; Hoshino A; Sugaya T; Nakano M; Hiraishi H
Scand J Gastroenterol; 2016 Jul; 51(7):827-34. PubMed ID: 26853910
[TBL] [Abstract][Full Text] [Related]
2. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
3. Mucosal Healing in Ulcerative Colitis--When Zero is Better.
Boal Carvalho P; Dias de Castro F; Rosa B; Moreira MJ; Cotter J
J Crohns Colitis; 2016 Jan; 10(1):20-5. PubMed ID: 26438714
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.
Nakarai A; Kato J; Hiraoka S; Inokuchi T; Takei D; Moritou Y; Akita M; Takahashi S; Hori K; Harada K; Okada H; Yamamoto K
World J Gastroenterol; 2014 Dec; 20(48):18367-74. PubMed ID: 25561804
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis.
Ikeya K; Sugimoto K; Kawasaki S; Iida T; Maruyama Y; Watanabe F; Hanai H
Dig Liver Dis; 2015 May; 47(5):365-71. PubMed ID: 25682993
[TBL] [Abstract][Full Text] [Related]
6. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.
Nakarai A; Kato J; Hiraoka S; Takashima S; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H
World J Gastroenterol; 2016 Jun; 22(21):5079-87. PubMed ID: 27275100
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial.
Fukuda T; Aoki Y; Kiyohara H; Yokoyama A; Nakazawa A; Yoshimatsu Y; Sugimoto S; Nanki K; Mikami Y; Fukuhara K; Mizuno S; Sujino T; Mutaguchi M; Takabayashi K; Morohoshi Y; Hosoda Y; Ogata H; Iwao Y; Naganuma M; Kanai T
Inflamm Bowel Dis; 2024 Apr; ():. PubMed ID: 38655866
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Dulai PS; Singh S; Jairath V; Ma C; Narula N; Vande Casteele N; Peyrin-Biroulet L; Vermeire S; D'Haens G; Feagan BG; Sandborn WJ
Aliment Pharmacol Ther; 2020 Feb; 51(4):435-445. PubMed ID: 31755121
[TBL] [Abstract][Full Text] [Related]
9. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.
Fukuda T; Naganuma M; Sugimoto S; Nanki K; Mizuno S; Mutaguchi M; Nakazato Y; Inoue N; Ogata H; Iwao Y; Kanai T
PLoS One; 2017; 12(11):e0187737. PubMed ID: 29108025
[TBL] [Abstract][Full Text] [Related]
10. Is mucosal healing more common than clinical remission in ulcerative colitis? - Is it the truth or only a myth coming from the studies?
Rutka M; Milassin Á; Szepes Z; SzŰcs M; Nyári T; Bálint A; Bor R; Molnár T; Farkas K
Scand J Gastroenterol; 2015 Aug; 50(8):985-90. PubMed ID: 25733077
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis.
Takenaka K; Tominaga K; Kanazawa M; Fukushi K; Tanaka T; Kanamori A; Sugaya T; Tsuchida K; Iijima M; Goda K; Irisawa A
Sci Rep; 2019 Nov; 9(1):17751. PubMed ID: 31780764
[TBL] [Abstract][Full Text] [Related]
12. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.
Madarame A; Fukuzawa M; Yamauchi Y; Kono S; Sugimoto A; Yamaguchi H; Morise T; Koyama Y; Uchida K; Suguro M; Matsumoto T; Yasuyuki K; Kawai T; Itoi T
PLoS One; 2021; 16(8):e0255620. PubMed ID: 34347848
[TBL] [Abstract][Full Text] [Related]
14. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
15. Histological healing as a predictor of sustained clinical remission in paediatric ulcerative colitis.
Scarallo L; Fioretti L; Paci M; Naldini S; Renzo S; Barp J; Gissi A; Di Paola M; Villanacci V; Lionetti P
Dig Liver Dis; 2024 Jan; 56(1):43-49. PubMed ID: 37455156
[TBL] [Abstract][Full Text] [Related]
16. Limited endoscopic mucosal inflammation on equivalent to Mayo endoscopic subscore of 0 unaffect clinical relapse of ulcerative colitis.
Shimodaira Y; Watanabe K; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Scand J Gastroenterol; 2022 Feb; 57(2):165-168. PubMed ID: 34663142
[TBL] [Abstract][Full Text] [Related]
17. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation.
Suzuki Y; Uchiyama K; Kato M; Matsuo K; Nakagawa T; Kishikawa H; Kimura N; Kasanuki J; Ino S
J Clin Gastroenterol; 2015; 49(5):401-6. PubMed ID: 25127112
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of linked color imaging for the endoscopic diagnosis of mucosal healing in quiescent ulcerative colitis.
Takagi T; Uchiyama K; Kajiwara-Kubota M; Kashiwagi S; Toyokawa Y; Hotta Y; Tanaka M; Inoue K; Dohi O; Yoshida N; Kamada K; Ishikawa T; Konishi H; Kishimoto M; Yagi N; Naito Y; Itoh Y
J Gastroenterol Hepatol; 2021 Sep; 36(9):2448-2454. PubMed ID: 33710655
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Endoscopic Inflammation and Mucosal Healing on Health-related Quality of Life in Ulcerative Colitis Patients.
Theede K; Kiszka-Kanowitz M; Nordgaard-Lassen I; Mertz Nielsen A
J Crohns Colitis; 2015 Aug; 9(8):625-32. PubMed ID: 25956537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
